drugset / Trial / NCT04464798
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This Phase 1/2, multicenter, open-label study to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification. Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion).
Timeline
- Start
- 2020-11-11
- Primary completion
- 2023-01-31
- Completion
- 2025-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iberdomide | Small molecule | — | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 1400 mg | Subcutaneous |